Xenetic Biosciences Extends Collaboration with Scripps Research to Advance DNase Platform.

Xenetic Biosciences has extended its collaboration with Scripps Research to advance its DNase platform. The company's systemic DNase I candidate, XBIO-015, is in preclinical development for combination with CAR-T cell therapy for both hematologic and solid tumors. The collaboration aims to explore the full potential of Xenetic's DNase-based oncology platform.